论文部分内容阅读
目的:观察通塞脉片对大鼠动脉粥样硬化(AS)的治疗作用并探讨其作用机理。方法:空白对照组喂以SPF级实验鼠颗粒饲料,其余通过饲喂高脂饲料及每周灌胃予以维生素D315万U/kg1次建立大鼠AS模型,分为4组,即模型组、辛伐他汀组(0.003g/kg)、通塞脉片高剂量组(12.44g/kg)、通塞脉片低剂量组(6.22g/kg)。给药容积为10ml/kg,每日1次,连续给药8周,观察其对血脂代谢及NF-КB、MCP-1等炎症因子在血管中表达情况。结果:在对AS大鼠血脂的影响试验中,通塞脉片高剂量组、低剂量组与空白组相比有显著性差异(P<0.01)。MCP-1在辛伐他汀和通塞脉片高剂量组阳性表达明显减少;NF-КB在空白组大鼠主动脉中表达较少,模型组呈强阳性表达,给药组呈中等阳性表达,表明通塞脉片浸膏可以显著改善AS大鼠血清中脂质紊乱现象,抑制血管中炎症因子的表达。结论:通塞脉片浸膏通过降低体内的炎症因子水平而起到治疗AS的作用。
Objective: To observe the therapeutic effect of Tongsaimai tablet on atherosclerosis (AS) in rats and its mechanism of action. Methods: The blank control group was fed with SPF experimental rat pellet feed, and the rest were fed with high fat diet and weekly gavage with Vitamin D3 1.5 million U / kg once to establish rat AS model, divided into four groups, model group, Xin The rats in the statin group (0.003g / kg), Tongsianmai tablet high dose group (12.44g / kg) and Tongsaimailian tablet low dose group (6.22g / kg). The volume of administration was 10ml / kg, once daily for 8 weeks. The effects on blood lipid metabolism and the expression of NF-КB, MCP-1 and other inflammatory factors in blood vessels were observed. Results: In the experiment of the influence on the blood lipid of AS rats, there was a significant difference between the high-dose and low-dose Tongsianmai tablets group and the blank group (P <0.01). The positive expression of MCP-1 in simvastatin and Tongsaimailian high-dose group was significantly reduced; NF-КB was less expressed in the aorta of the blank group, the expression of NF-КB was strongly positive in the model group, Tongsanmai extract can significantly improve the serum lipid in rats AS phenomenon, inhibit the expression of inflammatory cytokines. Conclusion: Tongsaimai tablet can play an active role in the treatment of AS by reducing the level of inflammatory cytokines in the body.